The vaccination campaign in Europe received another setback on Friday 15 January, when Pfizer-BioNotech announced that it would not provide Twenty-Seven the amount it would have to provide to distribute to them each week. The lab called for the need to work at its Belgian factory in Pursa, to expand its production capacity and to declare “Order and delivery schedules fluctuate”.
An announcement ending several European countries, specifically the Pfizer-BioNTech vaccine, requires four weeks in addition to two injections, and they now fear they won’t always be able to remember. German government removed “An unexpected and very short-lived communication” And asked the European Commission, which negotiated on behalf of Twenty-Seven to guarantee the vaccine order “Clarity and Security” For the rest of the process. In a joint letter on Friday afternoon, the health ministers of Denmark, Estonia, Finland, Lithuania, Latvia and Sweden condemned a situation for their part “not acceptable” Prejudiced “Reliability of the vaccination process”.
During a press conference in Lisbon, the chairman of the European Commission, Ursula von der Leyen, wanted to be convinced. “I called Pfizer’s boss, they assured me that deliveries that were planned for the first quarter would actually be in the first 30”, he said. The contract was signed between the Commission and six laboratories (Pfizer-BioNotech, Modern, Curevac, Johnson & Johnson, AstraZeneca, Sanofi-GSK) before it was confirmed – if all vaccines were to obtain marketing authorization. They will allow 2.3 billion doses to get their hands on twenty-seven doses “Huge success”.
In his own way, however, Ursula von der Leyen produced two cavites. The first was, of course, at Pfizer-BioNotech. The Commission has invested € 2.1 billion for six laboratories to help manufacturers “Invest in their production capacity”, she remembers, “But we hope they will honor their delivery schedule”.
The second target is Berlin, which has signed a memorandum of understanding with two laboratories, Pfizer-BioNotech and Curevac, and is still in discussions with Modern to buy them out-of-contract vaccines between the Commission and these groups. “Because we didn’t want to undermine the bargaining power of 450 million European citizens, Chairman of European Executive, launched The legal basis is very clear. No parallel negotiations, no parallel contracts ”.
You have 23.3% to read this article. The rest is for subscribers only.